Health · Pharma & Biotech · 8 hrs ago
Anvisa approves five new medicines for diabetes and obesity
Brazil’s Anvisa approved five new medicines based on liraglutide and semaglutide, for treating type 2 diabetes or obesity.
The new brands are Aribet, Sevema and Embeltah for diabetes, and Lyrza and Wylovol for obesity alongside changes to diet and exercise.
The reported 2026 approval totals differ: Folha says 19 medicines have been approved this year, while CNN Brasil says 20.
These medicines act on the GLP-1 system, helping regulate blood sugar and appetite.
Approval does not make the medicines interchangeable; the approved use, dose and a patient’s health needs matter when choosing treatment.
Treatment can require months or years, and cost and possible effects such as nausea or abdominal pain can affect whether a medicine is suitable.
An oral GLP-1 medicine called orforglipron is expected to reach Brazil in the second half of 2027, while other candidates remain in late-stage trials.
Brazil’s health regulator approved five new GLP-1 medicines on October 29 for diabetes or obesity.
The medicines contain liraglutide or semaglutide and are sold as Aribet, Lyrza, Wylovol, Embeltah and Sevema.
Aribet, Embeltah and Sevema are indicated for diabetes, while Lyrza and Wylovol are indicated for obesity alongside diet and exercise changes.
Folha reported that 19 such medicines had been approved in Brazil in 2026, while CNN Brasil reported a total of 20.
The articles say treatment choices should reflect each medicine’s approved indication, dose and patient needs.
- Who
- Brazil’s National Health Surveillance Agency (Anvisa).
- What
- It approved five new medicines containing liraglutide or semaglutide for diabetes or obesity.
- When
- October 29, 2026.
- Where
- Brazil.
- Why
- The medicines are intended to treat diabetes or obesity; the articles do not state a specific reason for the approvals.
This story does not have two clearly opposing sides.
Anvisa approved Ozivy, described by Folha as the first semaglutide medicine registered after the substance’s patent expired.
Ozivy joined Anvisa’s List of Reference Medicines.
Anvisa approved five semaglutide medicines, Folha reported.
Anvisa approved five new liraglutide- and semaglutide-based medicines.
- New approvals
- 5 medicines
- Active ingredients
- Liraglutide and semaglutide
- Diabetes brands
- Aribet, Embeltah and Sevema
- Obesity brands
- Lyrza and Wylovol
- Approval date
- October 29, 2026
- 2026 total
- Folha reported 19; CNN Brasil reported 20